A practical reference on 瑞他鲁肽: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Veratridine is a steroidal alkaloid found in plants related to lilies, specifically the genera Veratrum and Schoenocaulon. Upon absorption through the skin or mucous membranes, it acts as a neurotoxin by binding to and preventing the inactivation of voltage-gated sodium ion channels in heart, nerve, and skeletal muscle cell membranes. Veratridine increases nerve excitability and intracellular Ca2+ concentrations.
Plasma levels of progesterone are similar after vaginal and rectal administration in spite of the different routes of administration, and rectal administration is an alternative to vaginal progesterone in conditions of vaginal infection, cystitis, recent childbirth, or when barrier contraception methods are used. Intramuscular injection of progesterone may achieve much higher levels of progesterone than normal luteal phase concentrations and levels achieved with other routes.
=== 24 February === The SAF claimed to have taken the eastern part of the Soba Bridge. The SAF said that it had partially broken the siege of Dalang and captured the Al-Karkal, Koli, and Kiqa regions north of Kadugli and Hajar Al-Jawad and Karkariya to the south. The RSF claimed to have shot down an Ilyushin fighter jet over Nyala, killing its crew. The pilot was later identified as Major General Abulgasem Ali. The National Umma Party removed Fadlallah Burma Nasir as its acting leader following his cosigning of the Government of Peace and Unity agreement with the RSF. In response, Nasir ordered the dissolution of the party's Presidential Institution.
Sources: en.wikipedia.org
In February 2026, SF Airlines signed a 2026 cooperation memorandum with China Cargo Airlines, a subsidiary of EAL; the two parties plan to collaborate on capacity swaps on key routes such as Shanghai Pudong—Los Angeles and Shenzhen—Los Angeles, and jointly develop interline products from Southeast Asia to Europe and the US. In the same month, SF launched an income boost plan for its frontline employees nationwide, investing 200 million RMB to help all couriers increase their income, with an average raise of around 500 RMB per person. In addition, as the end of February, SF Holding had spent nearly 2 billion RMB on share buybacks, repurchasing 50.96 million A-shares, which accounts for 1.01% of its total shares.
=== Acquisition and merging of Novartis' vaccine business === In October 2014, Novartis announced its intention to sell its influenza vaccine business, including its development pipeline, to CSL for $275 million. CSL merged it into its BioCSL operation. In November 2015, BioCSL rebranded the combined business with Novartis Influenza Vaccines as Seqirus [Sek-eer-us], creating the world's second-largest influenza vaccine company. In August 2017, the business announced it would acquire Calimmune and its stem cell therapy platform. Completed in 2018, Seqirus's plant in Holly Spring, NC was funded with $59 million from the U.S. government. in June 2020, CSL announced it would exercise its right to acquire Vitaeris. In December 2021, the business announced it would acquire Swiss drugmaker, Vifor Pharma AG, for $11.7 billion. In August 2022, CSL rebranded all of its divisions to start with the CSL name. Therefore, the divisions became CSL Behring, CSL Plasma, CSL Seqirus, and CSL Vifor.
Experiments of other scientists, at first, produced the same results but later it became clear that the period of reinforced activity is followed by a period of decline. At the moment of the experiment Charles-Édouard Brown-Séquard was 72 years old. After the experiment he claimed he felt as if he became younger by 30 years. However, 5 years later he died. But other doctors picked up this method and it created the foundation for the development of hormone replacement therapy. 1903 Ilya Mechnikov coined the term "gerontology". The term originates from the Greek γέρων, geron, "old man" and -λογία, -logia, "study of". From 1897 to 1916 Mechnikov conducted many studies on the effect of acidified dairy products (especially Bulgarian yogurt and bacteria used for its production) on longevity and quality of life in old age. He developed the concept of probiotic diet that promotes long healthy life. In 1908 Mechnikov received the Nobel Prize for his work on immunology (adjacent area of his research). Adhering to his diet, Mechnikov lived a very long life compared to his short-lived relatives. 1914 Dr. Frank Lydston from Chicago performed human testis transplants on several patients, including himself, and said that there were some rejuvenating consequences (such as returning his gray hair to its original color and improving of sexual performance). These works remained little known. The work of Leo L. Stanley, that he began to do since 1919, received much more prominence (see further).
Sources: en.wikipedia.org
Lucas, the youngest Marine to receive the Medal of Honor, who then re-enlisted and became a Captain in the 82nd Senator Dave McCormick (born 1965), Captain who served in the Gulf War Wes Moore, 63rd governor of Maryland Platoon Forward Observer and Member of USA National Bobsled Team Lou Moreira Country music singer Craig Morgan (born 1964) Patrick Murphy, Under Secretary of the Army (born 1973) Actor Noble Craig, Vietnam War R&B singer Lou Rawls Sergeant in B Co 2/505 ABN INF 1956–58 Senator Jack Reed (born 1949) Dennis Richmond, journalist Syracuse University football coach Ben Schwartzwalder General "Henry" Hugh Shelton (Chairman of the Joint Chiefs of Staff from 1997 to 2001) Private John Steele who famously got hung up on a parapet of the church bell tower when jumping into Sainte-Mère-Église during the first hours of D-Day. Senator Strom Thurmond (325th Glider Infantry Regiment in World War II) Actor William Windom Colonel Benjamin H. Vandervoort who led the 2nd Battalion, 505th PIR on D-Day and the 3rd Battalion, 504th PIR during Operation Market Garden. Sergeant Alvin C. York (Medal of Honor recipient), World War I Trae Stewart Spurlock a 2x combat veteran killed by the Casper Police Department James Megellas One of the most decorated veterans of the 82nd
In 1966, E. O. Wilson and his colleagues identified the fossil remains of an ant (Sphecomyrma) that lived in the Cretaceous period. The specimen, trapped in amber dating back to around 92 million years ago, has features found in some wasps, but not found in modern ants. The oldest fossils of ants date to the mid-Cretaceous, around 113–100 million years ago, which belong to extinct stem-groups such as the Haidomyrmecinae, Sphecomyrminae and Zigrasimeciinae, with modern ant subfamilies appearing towards the end of the Cretaceous around 80–70 million years ago. Ants diversified extensively during the Angiosperm Terrestrial Revolution and assumed ecological dominance around 60 million years ago. Some groups, such as the Leptanillinae and Martialinae, are suggested to have diversified from early primitive ants that were likely to have been predators underneath the surface of the soil. During the Cretaceous period, a few species of primitive ants ranged widely on the Laurasian supercontinent (the Northern Hemisphere). Their representation in the fossil record is poor, in comparison to the populations of other insects, representing only about 1% of fossil evidence of insects in the era. Ants became dominant after adaptive radiation at the beginning of the Paleogene period. By the Oligocene and Miocene, ants had come to represent 20–40% of all insects found in major fossil deposits. Of the species that lived in the Eocene epoch, around one in 10 genera survive to the present.
On the other hand, if the idea of a smaller Germany won out, the German crown could of course not possibly go to the Emperor of Austria, but would naturally be offered to the head of the largest and most powerful German state outside of Austria—the King of Prussia. The contest between the two ideas, quickly developed into a contest between Austria and Prussia. After Prussia decisively won the Seven Weeks War, this question was solved; Austria lost no territories to Prussia as long as they remained out of German affairs.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。